6,760 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Bought by Northstar Advisory Group LLC

Northstar Advisory Group LLC purchased a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 6,760 shares of the company’s stock, valued at approximately $907,000. Intellia Therapeutics makes up about 0.9% of Northstar Advisory Group LLC’s investment portfolio, making the stock its 26th biggest position.

Several other institutional investors also recently bought and sold shares of the stock. Silicon Hills Wealth Management LLC lifted its position in shares of Intellia Therapeutics by 1.3% during the 2nd quarter. Silicon Hills Wealth Management LLC now owns 8,620 shares of the company’s stock valued at $1,396,000 after buying an additional 107 shares during the last quarter. Principal Financial Group Inc. increased its stake in Intellia Therapeutics by 0.6% in the 1st quarter. Principal Financial Group Inc. now owns 24,981 shares of the company’s stock worth $2,005,000 after acquiring an additional 157 shares during the last quarter. Advisory Services Network LLC bought a new position in shares of Intellia Therapeutics during the 2nd quarter valued at about $32,000. Itau Unibanco Holding S.A. bought a new position in shares of Intellia Therapeutics during the 2nd quarter valued at about $47,000. Finally, Sterling Investment Advisors Ltd. bought a new position in Intellia Therapeutics during the 2nd quarter worth approximately $49,000. 82.71% of the stock is currently owned by institutional investors.

In other Intellia Therapeutics news, EVP Laura Sepp-Lorenzino sold 97,000 shares of the business’s stock in a transaction on Monday, August 30th. The shares were sold at an average price of $154.83, for a total value of $15,018,510.00. Following the completion of the transaction, the executive vice president now owns 3,191 shares in the company, valued at $494,062.53. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Glenn Goddard sold 3,482 shares of Intellia Therapeutics stock in a transaction on Tuesday, September 7th. The stock was sold at an average price of $180.12, for a total transaction of $627,177.84. The disclosure for this sale can be found here. Insiders sold a total of 228,521 shares of company stock worth $35,866,181 over the last three months. Corporate insiders own 3.90% of the company’s stock.

Shares of Intellia Therapeutics stock opened at $115.52 on Thursday. The firm has a market capitalization of $8.49 billion, a PE ratio of -34.38 and a beta of 2.03. Intellia Therapeutics, Inc. has a twelve month low of $34.40 and a twelve month high of $202.73. The firm’s 50-day moving average price is $134.54 and its 200 day moving average price is $127.14.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, November 4th. The company reported ($0.97) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.85) by ($0.12). The company had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $8.66 million. Intellia Therapeutics had a negative net margin of 854.10% and a negative return on equity of 34.22%. The company’s quarterly revenue was down 67.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.47) earnings per share. On average, equities analysts anticipate that Intellia Therapeutics, Inc. will post -3.5 EPS for the current fiscal year.

NTLA has been the subject of a number of research analyst reports. Guggenheim initiated coverage on Intellia Therapeutics in a research note on Tuesday, October 5th. They issued a “buy” rating and a $170.00 target price for the company. Stifel Nicolaus assumed coverage on Intellia Therapeutics in a report on Thursday, September 23rd. They issued a “buy” rating and a $173.00 target price for the company. The Goldman Sachs Group lifted their price objective on Intellia Therapeutics from $225.00 to $252.00 and gave the stock a “buy” rating in a report on Friday, August 6th. Raymond James lifted their price objective on Intellia Therapeutics from $168.00 to $181.00 and gave the stock an “outperform” rating in a report on Friday, August 6th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $177.00 price objective on shares of Intellia Therapeutics in a report on Thursday, September 16th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $146.28.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

Featured Article: Market Timing – The Benefits and the Danger

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.